【摘要】 目的:研究IFN-α对慢性髓系白血病(CML)患者血清中细胞因子的影响。方法:选取我院2012年3月至2015年12月确诊为CML患者50例,通过随机数表法分为常规治疗组(n=25)和复合治疗组(n=25),选择30例健康人员作为对照组。给予常规治疗组和复合治疗组患者口服羟基脲,在常规治疗组的治疗基础上给予复合治疗组重组人干扰素α2b注射液。采用ELISA法检测血液中ALP、IL-6、PGE-2、MMP-2、及bFGF含量,对比对照组和CML组、CML慢性期和CML急变期组的上述指标的变化,记录治疗6周后细胞遗传学、分子学和血液学的疗效。结果:CML慢性期患者和急变期患者血清中ALP、IL-6、PGE-2、MMP-2及bFGF的含量均明显高于对照组(P<0.05);CML慢性期患者血清中的MMP-2和bFGF的含量高于CML急变期患者(P<0.05);CML慢性期患者的ALP、PGE-2和IL-6水平明显低于CML加速急变期患者(P<0.05);治疗2周、6周后复合治疗组的ALP、IL-6、PGE-2、MMP-2及bFGF水平均显著低于常规治疗组(P<0.05);治疗结束后常规治疗组的完全血液学缓解率(CHR)为56%,低于复合治疗组的84%(x~2=18.667,P<0.001);常规治疗组的完全细胞遗传学缓解(CCyR)为32%,明显高于复合治疗组的12%(x~2=11.655,P<0.001);常规治疗组的完全分子学缓解(CMR)为12%,显著高于复合治疗组的4%(x~2=4.347,P=0.037)。随访中,常规治疗组中位生存期显著短于复合治疗组,但差异无显著意义(P>0.05)。结论:IFN-α能缓解CML患者的症状,抑制CML进程,有效抑制相关疾病细胞因子的表达。更多还原

【Abstract】 Objective:To investigate the effect of IFN-α on cytokines in serum of patients with chronic myeloid leukemia(CML).Methods:Fifty patients with CML from March 2012 to December 2015 in our hospital were randomly divided into routine treatment group(n = 25) and combined treatment group(n = 25),30 healthy persons were selected as control(control group).The CML patients in routine treatment group were given orally hydroxyurea,the CML patients in combined treatment group were treated with recombinant human interferon a2 b injection based on routine treatment(hydroxyurea plus IFN-a group).The levels of ALP,IL-6,PGE-2,MMP-2,and bFGF in serum were detected by ELISA.The cytogenetic,molecular and hematologic responses of patients in routine treatment group and combined treatment group,including patients in chronic and accelerated blastic phases were compared after 6 weeks of treatment.Results:The servum levels of ALP,EL-6,PGE-2,MMP-2 and bFGF in CML patients with chronic and accelerated blastic phases all were higher than those in control group(P < 0.05).The levels of MMP-2 and bFGF in CML patients with chronic phase were highr than those of CML patients with accelerated blastic phase(P < 0.05),the levels of ALP,PGE-2 and IL-6 of patients with chronic phase were significantly lower than those of patients in accelerated blastic phase(P < 0.05).The ALP,IL-6,PGE-2,MMP-2 and bFGF levels in combined treatment group were significantly lower than those in the routine treatment group after 2 weeks and 6 weeks of treatment(P < 0.05);After the end of treatment,the CHR of routine treatment group was 56%,which was lower than that of combined treatment group 84%(x~2 = 18.667,P <0.001);the CCyR of routine treatment group was 32%which was significantly higher than 12%in combined treatment group(x~2 =11.655,P <0.001);the CMR of routine treatment group was 12%that was significantly higher than 4%in combined treatment group(x~2 =4.347,P = 0.037).The median survival time of routine treatment group was significantly shorter than that of the combined treatment group,but there was no significant difference during follow-up(P > 0.05).Conclusion;IFN-a can alleviate the symptoms of patients with CML and inhibit the process of disease with CML patients,effectively inhibit the expression of disease- related cytokines.更多还原